127 related articles for article (PubMed ID: 8917194)
1. Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma.
Brandau W; Niehoff T; Pulawski P; Jonas M; Dutschka K; Sciuk J; Coenen HH; Schober O
J Nucl Med; 1996 Nov; 37(11):1865-71. PubMed ID: 8917194
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of iodine-123-IMBA for melanoma imaging.
Nicholl C; Mohammed A; Hull WE; Bubeck B; Eisenhut M
J Nucl Med; 1997 Jan; 38(1):127-33. PubMed ID: 8998166
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma.
Michelot JM; Moreau MF; Labarre PG; Madelmont JC; Veyre AJ; Papon JM; Parry DF; Bonafous JF; Boire JY; Desplanches GG
J Nucl Med; 1991 Aug; 32(8):1573-80. PubMed ID: 1869982
[TBL] [Abstract][Full Text] [Related]
4. Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM).
Maffioli L; Mascheroni L; Mongioj V; Gasparini M; Baldini MT; Seregni E; Castellani MR; Cascinelli N; Buraggi GL
J Nucl Med; 1994 Nov; 35(11):1741-7. PubMed ID: 7965150
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, radiolabeling, and preliminary evaluation in mice of some (N-diethylaminoethyl)-4-iodobenzamide derivatives as melanoma imaging agents.
Moreau MF; Michelot J; Papon J; Bayle M; Labarre P; Madelmont JC; Parry D; Boire JY; Moins N; Seguin H
Nucl Med Biol; 1995 Aug; 22(6):737-47. PubMed ID: 8535334
[TBL] [Abstract][Full Text] [Related]
6. N-(2-diethylaminoethyl)-4-[123I]iodobenzamide as a tracer for the detection of malignant melanoma: simple synthesis, improved labelling technique and first clinical results.
Brandau W; Kirchner B; Bartenstein P; Sciuk J; Kamanabrou D; Schober O
Eur J Nucl Med; 1993 Mar; 20(3):238-43. PubMed ID: 8462613
[TBL] [Abstract][Full Text] [Related]
7. Preparation and biologic evaluation of a novel radioiodinated benzylpiperazine, 123I-MEL037, for malignant melanoma.
Pham TQ; Berghofer P; Liu X; Greguric I; Dikic B; Ballantyne P; Mattner F; Nguyen V; Loc'h C; Katsifis A
J Nucl Med; 2007 Aug; 48(8):1348-56. PubMed ID: 17631542
[TBL] [Abstract][Full Text] [Related]
8. A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)4-iodobenzamide.
John CS; Bowen WD; Saga T; Kinuya S; Vilner BJ; Baumgold J; Paik CH; Reba RC; Neumann RD; Varma VM
J Nucl Med; 1993 Dec; 34(12):2169-75. PubMed ID: 8254405
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic value of 123iodine-ibzm scintigraphy for staging of malignant melanomas].
Henker C; Bida B; Markwardt J; Schlag P
Nuklearmedizin; 1997 Jan; 36(1):1-6. PubMed ID: 9082335
[TBL] [Abstract][Full Text] [Related]
10. Limited sensitivity of iodine-123-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl ] benzamide whole-body scintigraphy in patients with malignant melanoma: a comparison with thallium-201 imaging.
Brenner W; Klomp HJ; Bohuslavizki KH; Szonn B; Kampen WU; Henze E
Eur J Nucl Med; 1999 Dec; 26(12):1567-71. PubMed ID: 10638408
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents.
Moins N; Papon J; Seguin H; Gardette D; Moreau MF; Labarre P; Bayle M; Michelot J; Gramain JC; Madelmont JC; Veyre A
Nucl Med Biol; 2001 Oct; 28(7):799-808. PubMed ID: 11578901
[TBL] [Abstract][Full Text] [Related]
12. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo.
Larisch R; Schulte KW; Vosberg H; Ruzicka T; Müller-Gärtner HW
J Nucl Med; 1998 Jun; 39(6):996-1001. PubMed ID: 9627332
[TBL] [Abstract][Full Text] [Related]
13. [Phase 2 clinical study of 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnostic of primary and metastatic ocular melanoma].
Sillaire-Houtmann I; Bonafous J; Veyre A; Mestas D; D'Incan M; Moins N; Kemeny JL; Chossat F; Bacin F
J Fr Ophtalmol; 2004 Jan; 27(1):34-9. PubMed ID: 14968075
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma.
Pham TQ; Greguric I; Liu X; Berghofer P; Ballantyne P; Chapman J; Mattner F; Dikic B; Jackson T; Loc'h C; Katsifis A
J Med Chem; 2007 Jul; 50(15):3561-72. PubMed ID: 17602544
[TBL] [Abstract][Full Text] [Related]
15. In vitro studies on the cellular uptake of melanoma imaging aminoalkyl-iodobenzamide derivatives (ABA).
Dittmann H; Coenen HH; Zölzer F; Dutschka K; Brandau W; Streffer C
Nucl Med Biol; 1999 Jan; 26(1):51-6. PubMed ID: 10096501
[TBL] [Abstract][Full Text] [Related]
16. Examination of four 123I-labeled piperidine-based sigma receptor ligands as potential melanoma imaging agents: initial studies in mouse tumor models.
Waterhouse RN; Chapman J; Izard B; Donald A; Belbin K; O'Brien JC; Collier TL
Nucl Med Biol; 1997 Aug; 24(6):587-93. PubMed ID: 9316089
[TBL] [Abstract][Full Text] [Related]
17. 5-[123I/125I]iodo-2'-deoxyuridine in metastatic lung cancer: radiopharmaceutical formulation affects targeting.
Semnani ES; Wang K; Adelstein SJ; Kassis AI
J Nucl Med; 2005 May; 46(5):800-6. PubMed ID: 15872354
[TBL] [Abstract][Full Text] [Related]
18. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide).
Michelot JM; Moreau MF; Veyre AJ; Bonafous JF; Bacin FJ; Madelmont JC; Bussiere F; Souteyrand PA; Mauclaire LP; Chossat FM
J Nucl Med; 1993 Aug; 34(8):1260-6. PubMed ID: 8326382
[TBL] [Abstract][Full Text] [Related]
19. [Perspectives of scintigraphic diagnosis of malignant lymphoma using a new radiopharmaceutical].
Meyniel G; Michelot J; Moreau MF; Veyre A
C R Acad Sci III; 1990; 311(1):13-8. PubMed ID: 2125523
[TBL] [Abstract][Full Text] [Related]
20. Iodide benzamides for the in-vivo detection of melanoma and metastases.
Edreira MM; Pozzi OR
Melanoma Res; 2006 Feb; 16(1):37-43. PubMed ID: 16432454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
